3D Medicines Inc. Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by Zhou Feng, was filed 31 Jul 2026.
Who traded when
BuySaleSince the insiders bought
- +20.9%Entry HK$2.18 · Close 22 Oct 2026 HK$2.63
- +73.3%Entry HK$2.77 · Close at T+365 HK$4.80
- -37.6%Entry HK$5.51 · Close at T+365 HK$3.44
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 13,717,381 sharesShareXHKGHKEX:DA20260818E00286
- 10,000 shares@ HK$2.250.0034% mcap100.0% of flowShareXHKGHKEX:DA20260731E00089Canonical exit: 26 Oct 2026 (T+90)
- 10,500 shares@ HK$6.0012.6% of flowShareXHKGHKEX:DA20260114E00185
- 24,000 shares@ HK$5.1924.8% of flowShareXHKGHKEX:DA20260109E00042Canonical exit: 6 Apr 2026 (T+90)
- 10,000 shares@ HK$5.1610.3% of flowShareXHKGHKEX:DA20250718E00405Canonical exit: 13 Oct 2025 (T+90)
- 13,717,381 sharesShareXHKGHKEX:DA20250702E00238
- 13,858,381 sharesShareXHKGHKEX:DA20250702E00233
- 10,000 shares@ HK$3.8398.3% of flowShareXHKGHKEX:DA20250407E00483Canonical exit: 30 Jun 2025 (T+90)
- 22,000 shares@ HK$1.706.0% of flowShareXHKGHKEX:DA20250128E00018Canonical exit: 26 Feb 2025 (T+90)
- 10,000 shares@ HK$1.603.5% of flowShareXHKGHKEX:DA20250128E00016Canonical exit: 26 Feb 2025 (T+90)
- 10,000 shares@ HK$2.004.4% of flowShareXHKGHKEX:DA20250128E00013Canonical exit: 19 Feb 2025 (T+90)
- 43,000 shares@ HK$1.9713.6% of flowShareXHKGHKEX:DA20241128E00286Canonical exit: 20 Feb 2025 (T+90)
- 4,000 shares@ HK$2.221.4% of flowShareXHKGHKEX:DA20241119E00049Canonical exit: 13 Feb 2025 (T+90)
- 2,500 shares@ HK$2.370.9% of flowShareXHKGHKEX:DA20241119E00048Canonical exit: 5 Feb 2025 (T+90)
- 10,000 shares@ HK$2.405.2% of flowShareXHKGHKEX:DA20241031E00097Canonical exit: 28 Jan 2025 (T+90)
- 1,000 shares@ HK$2.540.4% of flowShareXHKGHKEX:DA20241031E00065Canonical exit: 19 Jan 2025 (T+90)
- 2,500 shares@ HK$2.511.0% of flowShareXHKGHKEX:DA20241031E00064Canonical exit: 15 Jan 2025 (T+90)
- 1,000 shares@ HK$2.790.4% of flowShareXHKGHKEX:DA20241031E00063Canonical exit: 13 Jan 2025 (T+90)
- 5,000 shares@ HK$3.042.3% of flowShareXHKGHKEX:DA20241031E00062Canonical exit: 7 Jan 2025 (T+90)
- 12,500 shares@ HK$3.436.6% of flowShareXHKGHKEX:DA20241010E00481Canonical exit: 6 Jan 2025 (T+90)
- 8,000 shares@ HK$4.175.1% of flowShareXHKGHKEX:DA20241010E00480Canonical exit: 5 Jan 2025 (T+90)
- 8,000 shares@ HK$2.653.2% of flowShareXHKGHKEX:DA20241010E00479Canonical exit: 2 Jan 2025 (T+90)
- 5,000 shares@ HK$3.802.9% of flowShareXHKGHKEX:DA20241010E00477Canonical exit: 1 Jan 2025 (T+90)
- 10,000 shares@ HK$4.026.1% of flowShareXHKGHKEX:DA20241003E00395Canonical exit: 31 Dec 2024 (T+90)
- 7,500 shares@ HK$3.383.8% of flowShareXHKGHKEX:DA20241003E00394Canonical exit: 29 Dec 2024 (T+90)
25 of 79 declarations
About 3D Medicines Inc.
On April 5, 2024, 7 directors of 3D Medicines Inc., a health care company listed in Hong Kong and valued at HKD 650.5 million, bought on the same day. The year 2024 holds 64 of the 79 filings published from December 21, 2022 to August 18, 2026.
Amounts are small and numerous: 52 purchases carry an amount, EUR 360,726 in all with a median of EUR 3,668, and 14 sales carry one, EUR 209,829 with a median of EUR 11,607. The largest purchases are all Zhu Pai's (Director), in November 2023: EUR 47,589 on the 8th, EUR 28,753 on the 9th and EUR 28,694 on the 6th. Zhu Pai also made the largest sales, EUR 56,085 on November 9, 2023, EUR 29,037 on the 6th and EUR 18,204 on the 8th.
Read moreShow less
Gong Zhaolong (Director) has 31 filings, 29 of them purchases; Zhu Pai has 31, with 16 purchases and 13 sales; ZHOU Feng has 11, including 10 purchases. The market side is 59 purchases against 14 sales (81% purchases). Directors hold 43.2% of the capital. Over twelve months: 4 filings, 2 purchases, one sale.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
